Alpine Immune Sciences Inc.
| NASDAQ: ALPN | Healthcare / Biotechnology / USA |
| 11.37 | -0.0800 | -0.70% | Vol 460.23K | 1Y Perf 59.03% |
| Oct 2nd, 2023 16:00 DELAYED |
| BID | 10.83 | ASK | 11.90 | ||
| Open | 11.36 | Previous Close | 11.45 | ||
| Pre-Market | - | After-Market | 11.37 | ||
| - - | - -% |
| Target Price | 13.75 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 20.93 | Finscreener Ranking | ★★★★★ 59.15 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 53.95 | |
| Insiders Value % 3/6/12 mo. | -/-/9 | Growth Ranking | ★★★+ 55.12 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/10 | Income Ranking | — - | |
| Price Range Ratio 52W % | 64.85 | Earnings Rating | Strong Buy | |
| Market Cap | 559.42M | Earnings Date | 13th Nov 2023 | |
| Alpha | 0.03 | Standard Deviation | 0.28 | |
| Beta | 1.27 |
Today's Price Range 11.0111.51 | 52W Range 4.8214.92 | 5 Year PE Ratio Range -5.80-1.80 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -4.69% | ||
| 1 Month | -11.86% | ||
| 3 Months | 12.13% | ||
| 6 Months | 40.54% | ||
| 1 Year | 59.03% | ||
| 3 Years | 26.61% | ||
| 5 Years | 89.82% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -39.98 | |||
ROE last 12 Months | -37.80 | |||
ROA (5Y Avg) | -12.97 | |||
ROA last 12 Months | -22.09 | |||
ROC (5Y Avg) | -42.14 | |||
ROC last 12 Months | -31.89 | |||
Return on invested Capital Q | -8.81 | |||
Return on invested Capital Y | -10.61 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 2.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -4.30 | ||||
| 1.93 | ||||
| 13.12 | ||||
| 39.30 | ||||
| -12.90 | ||||
| -1.34 | ||||
| 1.93 | ||||
| 3.96 | ||||
| 117.98M | ||||
| Forward PE | -7.78 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.60 | ||||
| 3.70 | ||||
| 0.05 | ||||
| 0.09 | ||||
| -91.70 | ||||
| Leverage Ratio | 1.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -163.50 | ||||
| -161.60 | ||||
| -1 746.90 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 27.29M | ||||
| 0.59 | ||||
| 256.15 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.38 | -0.27 | 28.95 |
| Q01 2023 | -0.37 | -0.28 | 24.32 |
| Q04 2022 | -0.27 | -0.41 | -51.85 |
| Q03 2022 | -0.10 | -0.42 | -320.00 |
| Q02 2022 | -0.39 | -0.60 | -53.85 |
| Q01 2022 | -0.17 | -0.25 | -47.06 |
| Q04 2021 | -0.26 | -0.52 | -100.00 |
| Q03 2021 | 0.01 | -0.55 | -5 600.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.34 | 10.53 | Positive |
| 12/2023 QR | -0.23 | 30.30 | Positive |
| 12/2023 FY | -1.18 | 17.48 | Positive |
| 12/2024 FY | -1.47 | 15.03 | Positive |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -0.34 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 460.23K |
| Shares Outstanding | 49.20K |
| Shares Float | 28.39M |
| Trades Count | 3.92K |
| Dollar Volume | 5.19M |
| Avg. Volume | 230.14K |
| Avg. Weekly Volume | 208.32K |
| Avg. Monthly Volume | 266.76K |
| Avg. Quarterly Volume | 215.34K |
Alpine Immune Sciences Inc. (NASDAQ: ALPN) stock closed at 11.37 per share at the end of the most recent trading day (a -0.7% change compared to the prior day closing price) with a volume of 460.23K shares and market capitalization of 559.42M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Alpine Immune Sciences Inc. CEO is Mitchell H. Gold.
The one-year performance of Alpine Immune Sciences Inc. stock is 59.03%, while year-to-date (YTD) performance is 54.69%. ALPN stock has a five-year performance of 89.82%. Its 52-week range is between 4.82 and 14.92, which gives ALPN stock a 52-week price range ratio of 64.85%
Alpine Immune Sciences Inc. currently has a PE ratio of -4.30, a price-to-book (PB) ratio of 1.93, a price-to-sale (PS) ratio of 13.12, a price to cashflow ratio of 39.30, a PEG ratio of -, a ROA of -22.09%, a ROC of -31.89% and a ROE of -37.80%. The company’s profit margin is -%, its EBITDA margin is -161.60%, and its revenue ttm is $27.29 Million , which makes it $0.59 revenue per share.
Of the last four earnings reports from Alpine Immune Sciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. Alpine Immune Sciences Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Alpine Immune Sciences Inc. is Strong Buy (1), with a target price of $13.75, which is +20.93% compared to the current price. The earnings rating for Alpine Immune Sciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Alpine Immune Sciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Alpine Immune Sciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.30, ATR14 : 0.64, CCI20 : -131.21, Chaikin Money Flow : -0.17, MACD : -0.33, Money Flow Index : 61.22, ROC : -4.13, RSI : 39.94, STOCH (14,3) : 19.89, STOCH RSI : 0.22, UO : 40.95, Williams %R : -80.11), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Alpine Immune Sciences Inc. in the last 12-months were:
Alpine Immune Sciences Inc.
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202.
CEO: Mitchell H. Gold
Telephone: +1 206 788-4545
Address: 188 East Blaine Street, Seattle 98102, WA, US
Number of employees: 53
